251 related articles for article (PubMed ID: 38293546)
1. Bibliometric analysis of research trends on the combination of immune checkpoint inhibitors and PARP inhibitors in solid tumors.
Tan Y; Song Q
Heliyon; 2024 Jan; 10(2):e24452. PubMed ID: 38293546
[TBL] [Abstract][Full Text] [Related]
2. A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011-2021.
Zhang H; Shi Y; Ying J; Chen Y; Guo R; Zhao X; Jia L; Xiong J; Jiang F
Front Endocrinol (Lausanne); 2023; 14():1164692. PubMed ID: 37152956
[TBL] [Abstract][Full Text] [Related]
3. Research hot spots and trends in endocrine-related adverse events caused by immune checkpoint inhibitors: a bibliometric analysis and visualization research.
Zhao J; Liu G; Yang X; Zhang C; Han B; Jiang M
Front Endocrinol (Lausanne); 2024; 15():1253832. PubMed ID: 38686201
[TBL] [Abstract][Full Text] [Related]
4. Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors.
Zeng L; Ma G; Chen K; Zhou Q
Front Immunol; 2023; 14():1242336. PubMed ID: 37869006
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events: A bibliometric analysis.
Jiang ST; Liu YG; Zhang L; Sang XT; Xu YY; Lu X
Front Immunol; 2022; 13():1096806. PubMed ID: 36591239
[TBL] [Abstract][Full Text] [Related]
6. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F; Italiano A
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
[TBL] [Abstract][Full Text] [Related]
7. Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.
Liu YG; Jiang ST; Zhang L; Zheng H; Zhang T; Zhang JW; Zhao HT; Sang XT; Xu YY; Lu X
Eur J Med Res; 2023 Jul; 28(1):229. PubMed ID: 37430294
[TBL] [Abstract][Full Text] [Related]
8. Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.
Chen X; He F; Zhang W; Fu Y; Cao Z
Front Oncol; 2023; 13():1092969. PubMed ID: 37124495
[TBL] [Abstract][Full Text] [Related]
9. Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021).
Yang S; Zhao S; Ye Y; Jia L; Lou Y
Front Immunol; 2022; 13():952546. PubMed ID: 36090978
[TBL] [Abstract][Full Text] [Related]
10. Emerging trends and research foci of oncolytic virotherapy for central nervous system tumors: A bibliometric study.
Cheng K; Zhang H; Guo Q; Zhai P; Zhou Y; Yang W; Wang Y; Lu Y; Shen Z; Wu H
Front Immunol; 2022; 13():975695. PubMed ID: 36148235
[TBL] [Abstract][Full Text] [Related]
11. Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.
Huang Y; Chen Z; Shen G; Fang S; Zheng J; Chi Z; Zhang Y; Zou Y; Gan Q; Liao C; Yao Y; Kong J; Fan X
Hum Vaccin Immunother; 2024 Dec; 20(1):2318815. PubMed ID: 38419524
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022.
Tan Y; Lu Y; Chen S; Zou C; Qin B
Front Oncol; 2023; 13():1161759. PubMed ID: 37324010
[TBL] [Abstract][Full Text] [Related]
13. Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis.
Zhang Y; Lu L; Zheng R
Front Pharmacol; 2023; 14():1140771. PubMed ID: 37214445
[No Abstract] [Full Text] [Related]
14. Knowledge-map analysis of bladder cancer immunotherapy.
Lv Z; Hou J; Wang Y; Wang X; Wang Y; Wang K
Hum Vaccin Immunother; 2023 Dec; 19(3):2267301. PubMed ID: 37903500
[TBL] [Abstract][Full Text] [Related]
15. Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study.
Zhong W; Shen Z; Wu Y; Mao X; Kong J; Wu W
Front Immunol; 2022; 13():1014981. PubMed ID: 36389756
[TBL] [Abstract][Full Text] [Related]
16. Global research trends in immunotherapy for glioma: a comprehensive visualization and bibliometric analysis.
Zhang HY; Yu HY; Zhao GX; Jiang XZ; Gao G; Wei BJ
Front Endocrinol (Lausanne); 2023; 14():1273634. PubMed ID: 37867521
[TBL] [Abstract][Full Text] [Related]
17. Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis.
Xu Y; Jiang Z; Kuang X; Chen X; Liu H
J Med Internet Res; 2022 Jun; 24(6):e32728. PubMed ID: 35759331
[TBL] [Abstract][Full Text] [Related]
18. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
Franzese O; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
[TBL] [Abstract][Full Text] [Related]
19. Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors.
Zhou L; Wan Y; Zhang L; Meng H; Yuan L; Zhou S; Cheng W; Jiang Y
Biomed Pharmacother; 2024 Jun; 175():116733. PubMed ID: 38754267
[TBL] [Abstract][Full Text] [Related]
20. Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis.
Zhang L; Zheng H; Jiang ST; Liu YG; Zhang T; Zhang JW; Lu X; Zhao HT; Sang XT; Xu YY
Int J Surg; 2024 Mar; 110(3):1699-1710. PubMed ID: 38181123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
